Literature DB >> 10312459

Reducing i.v. waste to under 2.25 percent.

J G Newhouse, V M Paul, N A Waugh, C B Frye.   

Abstract

Reduction of IV waste is of extreme importance in the maintenance of cost-effective, quality pharmacy services. This report describes the methods undertaken by a large community hospital to decrease IV waste to under 4%. The program uses several techniques including: "status sheets", IV reminder labels, commercial partial fill containers, extensive recycling procedures and close communication between the central IV service, pharmacy satellites and nursing units.

Mesh:

Substances:

Year:  1988        PMID: 10312459

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN: 0018-5787


  11 in total

1.  A survey of undergraduate and continuing medical education about antimicrobial chemotherapy in the United Kingdom. British Society of Antimicrobial Chemotherapy Working Party on Antimicrobial Use.

Authors:  P Davey; S Hudson; G Ridgway; D Reeves
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

2.  Direct costs of intravenous delivery systems.

Authors:  S W Birdwell
Journal:  Pharmacoeconomics       Date:  1993-07       Impact factor: 4.981

Review 3.  Pharmacoeconomics of intravenous drug administration.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

Review 4.  Pharmacoeconomics of antibacterial treatment.

Authors:  P G Davey; M M Malek; S E Parker
Journal:  Pharmacoeconomics       Date:  1992-06       Impact factor: 4.981

Review 5.  Treatment of urinary tract infection. Clinical and economic considerations.

Authors:  R J Plumridge; C L Golledge
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

6.  Identifying costs of intravenous solution wastage.

Authors:  K M Uchida; S A Iteen; N T Wong
Journal:  Pharmacoeconomics       Date:  1994-09       Impact factor: 4.981

7.  Defining criteria for the pharmacoeconomic evaluation of new oral cephalosporins.

Authors:  P G Davey; M Malek
Journal:  Pharmacoeconomics       Date:  1994       Impact factor: 4.981

Review 8.  Oral ciprofloxacin: a pharmacoeconomic evaluation of its use in the treatment of serious infections.

Authors:  J A Balfour; D Faulds
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

9.  Meropenem. A pharmacoeconomic review of its use in serious infections.

Authors:  S M Holliday; P Benfield
Journal:  Pharmacoeconomics       Date:  1998-03       Impact factor: 4.981

10.  Impact of Sterile Compounding Batch Frequency on Pharmaceutical Waste.

Authors:  Ghalib Abbasi; Evan Gay
Journal:  Hosp Pharm       Date:  2017-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.